CHANNEL THERAPEUTICS CORP (CHRO) Stock Price, Quote, News and Summary
NYSEARCA:CHRO - American Stock Exchange - US1711261057 - Common Stock
CHRO Quote and Key Statistics
CHANNEL THERAPEUTICS CORP
NYSEARCA:CHRO (1/17/2025, 8:04:02 PM)
After market: 2.06 +0.16 (+8.42%)1.9
+0.94 (+97.92%)
CHRO Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -222.66% | ||
| ROE | -794.3% | ||
| Debt/Equity | 0 |
CHRO Performance and Technical Analysis
CHRO Ownership and Analysts
CHRO Latest News and Analysis
Get insights into the top gainers and losers of Friday's after-hours session.
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
Let's take a look at the stocks that are in motion in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
What's going on in today's session
Which stocks are experiencing notable movement on Friday?
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical’s recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy.
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the...
About CHRO
Company Profile
Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. The company is headquartered in Freehold, New Jersey and currently employs 4 full-time employees. The company went IPO on 2024-02-16. Its clinical focus is to selectively target the sodium ion-channel, NaV1.7, which has been genetically validated as a pain receptor in human physiology. The company operates three programs developing pain treatment therapeutics: Neuropathic Pain, Eye Pain, and Depot. The company is engaged in developing, CC8464, to address certain types of neuropathic pain. The chemical characteristics of CC8464 restrict its entry into the CNS and limit its effect to the NaV1.7 channels in the peripheral nervous system. Based on a novel formulation of CC8464, its Eye Pain program, titled CT2000, is for the potential treatment of both acute and chronic eye pain. Based on several novel formulations of CC8464, its program, titled CT3000, is for the potential treatment of postoperative pain with the use of nerve blocks.
Company Info
CHANNEL THERAPEUTICS CORP
4400 Route 9 South, Suite 1000
Freehold NEW JERSEY US
Employees: 4
Company Website: https://ir.chromocell.com/
Phone: 18772658266
CHRO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.96 | 303.17B | ||
| AMGN | AMGEN INC | 14.16 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 20.73 | 114.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 827.45 | 108.68B | ||
| REGN | REGENERON PHARMACEUTICALS | 15 | 74.90B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 22.37B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.61 | 20.48B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.76 | 16.02B |